Arvinas to Present at 41st Annual J.P. Morgan Healthcare Conference
04 January 2023 - 11:00PM
Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology
company creating a new class of drugs based on targeted protein
degradation, today announced that John Houston, Ph.D., President
and Chief Executive Officer of Arvinas, will present a company
overview at the 41st Annual J.P. Morgan Healthcare Conference on
Wednesday, January 11, 2023 at 1:30 p.m. PT in San Francisco,
Calif.
A live audio webcast of the presentation will be available here
and on the Events & Presentations section of the Investors
& Media section of the Company’s website.
About ArvinasArvinas is a clinical-stage
biotechnology company dedicated to improving the lives of patients
suffering from debilitating and life-threatening diseases through
the discovery, development, and commercialization of therapies that
degrade disease-causing proteins. Arvinas uses its proprietary
PROTAC® Discovery Engine platform to engineer proteolysis targeting
chimeras, or PROTAC® targeted protein degraders, that are designed
to harness the body’s own natural protein disposal system to
selectively and efficiently degrade and remove disease-causing
proteins. In addition to its robust preclinical pipeline of PROTAC®
protein degraders against validated and “undruggable” targets, the
company has three investigational clinical-stage programs:
bavdegalutamide (ARV-110) and ARV-766 for the treatment of men with
metastatic castration-resistant prostate cancer; and ARV-471 for
the treatment of patients with locally advanced or metastatic
ER+/HER2- breast cancer. For more information,
visit www.arvinas.com.
Contacts
Investors:Jeff Boyle+1 (347)
247-5089Jeff.Boyle@arvinas.com
Media:Kirsten Owens+1 (203)
584-0307Kirsten.Owens@arvinas.com
Arvinas (NASDAQ:ARVN)
Historical Stock Chart
From Mar 2024 to Mar 2024
Arvinas (NASDAQ:ARVN)
Historical Stock Chart
From Mar 2023 to Mar 2024